US2005232940A1PendingUtilityA1
Recombinant plasmid and a method of controlling the effects of yersinia pestis
Est. expirySep 8, 2014(expired)· nominal 20-yr term from priority
A61K 39/00C07K 16/1228A61K 39/025C07K 14/24Y02A50/30
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Described is a plasmid prepared by recombinant techniques which is used to prepare a vaccine against Y. pestis.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . An immunogenic polypeptide substantially free of antigenic contaminating proteins, comprising an antigenic polypeptide sequence of the 259 C-terminal amino acids of V antigen.
11 . The immunogenic polypeptide of claim 10 , encoded by construct pAV13 shown in FIG. 1 .
12 . The immunogenic polypeptide of claim 10 , comprising 31.5 kDa of the 259 C-terminal amino acids of V antigen.
13 . The immunogenic polypeptide of claim 10 , comprising 19.3 kDa of the 259 C-terminal amino acids of V antigen.
14 . The immunogenic polypeptide of claim 12 , comprising a 31.5 kDa N-terminal portion of the 259 C-terminal amino acids of V antigen.
15 . The immunogenic polypeptide of claim 10 , comprising an antigenic polypeptide sequence of the 31.5 kDa N-terminal portion of the 259 C-terminal amino acids of V antigen.
16 . The immunogenic polypeptide of claim 15 , wherein the antigenic polypeptide sequence does not comprise a portion of the 19.5 kDa N-terminal portion of the 259 C-terminal amino acids of V antigen.
17 . A V antigen-based Y. pestis vaccine, comprising an antigenic polypeptide sequence of the 259 C-terminal amino acids of V antigen.
18 . The V antigen-based Y. pestis vaccine of claim 17 , wherein the antigenic polypeptide sequence is encoded by construct pAV13 shown in FIG. 1 .
19 . The V antigen-based Y. pestis vaccine of claim 17 , comprising 31.5 kDa of the 259 C-terminal amino acids of V antigen.
20 . The V antigen-based Y. pestis vaccine of claim 17 , comprising 19.3 kDa of the 259 C-terminal amino acids of V antigen.
21 . The V antigen-based Y. pestis vaccine of claim 19 , comprising a 31.5 kDa N-terminal portion of the 259 C-terminal amino acids of V antigen.
22 . The V antigen-based Y. pestis vaccine of claim 17 , comprising an antigenic polypeptide sequence of the 31.5 kDa N-terminal portion of the 259 C-terminal amino acids of V antigen.
23 . The V antigen-based Y. pestis vaccine of claim 22 , comprising an antigenic polypeptide sequence that is not a part of the 19.5 kDa N-terminal portion of the 259 C-terminal amino acids of V antigen.
24 . A polyclonal antiserum comprising antibodies that specifically binds to antigenic polypeptide sequences of the 259 C-terminal amino acids of V antigen.
25 . A polyclonal antiserum comprising antibodies that specifically bind to antigenic polypeptide sequences of the 31.5 kDa N-terminal portion of the 259 C-terminal amino acids of V antigen.
26 . The polyclonal antiserum of claim 25 , wherein the antiserum comprises antibodies that specifically bind to an antigenic polypeptide sequence that is not a part of the 19.5 kDa N-terminal portion of the 259 C-terminal amino acids of V antigen.
27 . An anti- Yersinia antiserum made by a method which comprises injecting a mammal with an immunogenic amount of an immunogenic polypeptide of any of claims 10 - 16 .
28 . An anti-bubonic plague antiserum made by a method which comprises injecting a mammal with an immunogenic amount of an immunogenic polypeptide of any of claims 10 - 16 .
29 . A method of treating or preventing a Yersinia infection in a mammal comprising administering an immunoprotective amount of an anti-V antigen antiserum raised against an immunogenic polypeptide of any of claims 10 - 16 .
30 . A method of treating or preventing bubonic plague in a mammal comprising administering an immunoprotective amount of an anti-V antigen antiserum raised against an immunogenic polypeptide of any of claims 10 - 16 .
31 . An isolated recombinant V protein antigen truncated at its N terminus by 67 amino acids and encoded by all but the 201 N-terminal base pairs of a V antigen gene.
32 . The truncated V protein of claim 31 , encoded by construct pAV13 shown in FIG. 1 .
33 . A method of controlling Y. pestis in a mammal, comprising:
(a) providing a vaccine comprised of the truncated V protein of claim 31; and (b) administering an effective immunizing amount of the vaccine to the mammal.
34 . A method of controlling Y. pestis in a mammal, comprising:
(a) providing a vaccine comprised of the truncated V protein of claim 32 and (b) administering an effective immunizing amount of the vaccine to the mammal.
35 . A method of treating a mammal infected with Y. pestis , comprising:
(a) providing a vaccine comprised of the truncated V protein of claim 31; and (b) administering an effective immunizing amount of the vaccine to the mammal.
36 . A method of treating a mammal infected with Y. pestis , comprising:
(a) providing a vaccine comprised of the truncated V protein of claim 32; and (b) administering an effective immunizing amount of the vaccine to the mammal.
37 . An isolated nucleic acid encoding an immunogenic polypeptide fragment of a V antigen protein.
38 . An isolated nucleic acid encoding the immunogenic polypeptide of any of claims 10 - 16 .Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.